

IN THE CLAIMS:

Please substitute currently amended claim number 26 for the original claim having the same claim number.

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Withdrawn) A pharmaceutical composition comprising a molecule targeted to a tissue selected from the group consisting of pulmonary circulation, intestinal circulation, pulmonary airways, lumen of the small intestine, dendritic cells in the skin and T cell areas of lymphoid organs, thymus, and brain, which molecule is conjugated to a DEC-ligand, which DEC-ligand is selected from the group consisting of a carbohydrate that binds DEC and an anti-DEC antibody, and a pharmaceutically acceptable carrier.

23. (Withdrawn) The pharmaceutical composition of claim 22, wherein the molecule is selected from the group consisting of an anti-cancer drug, an anti-viral drug, an antibiotic, an anti-parasitic drug, and an anti-inflammatory drug.

24. (Canceled)

25. (Canceled)

26. (Currently amended) A vaccine for inducing an immune response comprising an antigen from a pathogen conjugated to a Dendritic and Epithelial Cell-205 (DEC-205) ligand, wherein the DEC-205 ligand is an anti-human DEC-205 antibody or an anti-murine DEC-205 antibody reactive with a human DEC-205 protein, said human DEC-205 protein comprising an amino acid sequence as set forth in SEQ ID NOs: 2 or 13, and an immune stimulator.
27. (Original) The vaccine of claim 26, wherein the pathogen is selected from the group consisting of a virus, a bacterium, a parasite, and a tumor.
28. (Original) The vaccine of claim 26, wherein the immune stimulator is selected from the group consisting of a cytokine, a lymphokine, and an adjuvant.
29. (Withdrawn) A composition to induce immune suppression comprising an autoantigen or an allergen conjugated to a DEC-ligand, wherein the DEC ligand is selected from the group consisting of a carbohydrate that binds DEC and an anti-DEC antibody, with the proviso that the composition lack immune stimulatory agents.
30. (Withdrawn) The composition of claim 29, wherein the autoantigen is selected from the group consisting of myelin basic protein, collagen or a fragment thereof, DNA, a nuclear protein, a nucleolar protein, a mitochondrial protein, and a pancreatic β -cell protein.
31. (Canceled)
32. (Canceled)
33. (Canceled)
34. (Canceled)